ERBB2 and breast carcinoma: For patients with metastatic HER2(+), hormone receptor(-) breast cancer upon progressing with therapy with trastuzumab and chemotherapy, it is recommended to administer 1,000 mg of lapatinib in combination with trastuzumab (4).